The Antibiotic Resistant Superbug: Is it another Swine Flu on its way?
August 12th 2010
There is a new form of superbug that has been diagnosed in London and Nottingham recently. The enzyme known as NDM-1 is the single major threat to humanity in a unique way that has never been seen before. This gene has a power to enrich any bacteria in a way that it can take-over any anti-biotical treatment that may offered to cure its infection. Scientists and medical experts are seriously concerned about this traumatic situation in which this superbug attacks through gut or lungs and then creates urinary tract infection and poisons the bloodstream of the patient.
The superbug is believed to be originated from India as it has been observed to be carried over to the UK from Britons returning from India, Pakistan and Bangladesh. The superbug can gain the proportion of an international epidemic if strict measures are not following to control the gene. Huge population and unsafe hygiene environment is the major cause of its ferocity. It is also believed that it can be present in Australia, Canada, the US, the Netherlands and Sweden.
Medical tourism is supposed to be a major reason of the increase in the number of cases and spread of the superbug. These enzymes set-up their colonies on skin and enters the patients body through skin to blood-stream. Any form of surgery particularly the cosmetic is considered to be the main source of its spread, prominently from those recently returning from India after their skin treatments. Another Briton returning from Pakistan suffered skin trauma in Pakistan was later diagnosed in a very controlled environment to quarantine the bug from the institution treating these superbugs in the UK. The UK government has urged people at large to observe keen clean hygiene measures such as washing hands regularly and cleanliness to sabotage the spread of this dangerous gene/enzyme/superbug. There are almost 50 cases officially noticed in the UK.
It costs around £500 million to £1 billion to bring new drugs to market. GSK, one of the few actively involved and investing in anti-biotic research said: 'New antibiotics that work in different ways to existing medicines are desperately needed to tackle the rising incidence of antibiotics resistance.'
Others found this article:
swine flu | superbug flu | swine flu in india | flu superbug | antibiotic resistance | pakistan | swine flu uk | resistance | swine flu india | india flu |
